AlphAIAlphAI — Financial news for AI agents
BenzingaOCT 303 min read$PHAT

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Phathom Pharmaceuticals (NASDAQ:PHAT)

Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarter Full-year 2025 revenue guidance updated to $170-$175 million.

Original reporting
Benzinga · Globe Newswire
Published Oct 30, 2025, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2025, 11:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PHAT
Bullish
high confidence
Mentioned
$PHAT
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$PHATBullishHigh
01

Why it matters

The positive financial results and updated guidance suggest a favorable outlook, likely to attract investor interest and support stock appreciation.

02

Market read

The company's strong quarterly performance reinforces its position in the biotech sector, with potential to influence related stocks and sector indices.

03

What to watch

Potential regulatory hurdles or competitive pressures that could impact future growth are not addressed in this report.

Timing: Immediate to short-term trading window (next 1-2 days)

Background

Phathom Pharmaceuticals has demonstrated significant growth in prescription volume and revenue, indicating successful market penetration and product acceptance.

Company-level read

Ticker impact

$PHATBullishHigh confidence
Context

Highly relevant as the news pertains directly to Phathom Pharmaceuticals' financial results.

Expected impact

Potential short-term upward movement; estimated increase of 3-5% based on positive earnings data.

Evidence & confidence

Significant growth metrics and upward revision of full-year guidance support a bullish outlook in the near term.

Market effects

Sector

Positive sentiment for biotech and specialty pharma sectors due to strong prescription growth and revenue outlook.

Regional

Limited regional impact; primarily relevant to US markets where Phathom operates.

Global

Moderate; reflects ongoing growth in niche pharmaceutical markets, but limited global ripple effects.

Counterpoint

What could challenge this read

The strong quarterly results may already be priced in, and upcoming market volatility could negate short-term gains.

Key entities

  • Company
    Phathom Pharmaceuticals

    A biotech company specializing in gastrointestinal therapies, notably VOQUEZNA®.

  • Product
    VOQUEZNA®

    A treatment for certain gastrointestinal conditions, with over 790,000 prescriptions filled to date.

Read at source← All news

Related articles

SEP 29
$PHATMedAI 8/10

Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN…

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 29, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of

SEC EDGAR 8-K2 min
JUL 30
$PHATMed

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update • ~1.7 million total VOQUEZNA ® prescriptions filled to date • Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 • Q2 operatin

SEC EDGAR 8-K7 min
SEP 29
$LMTMedAI 8/10

Lockheed Martin (LMT) Secures $298 Million in New Defense Contra

Lockheed Martin (LMT) announced $298M in contract modifications for U.S. Navy and Japan's defense systems. The company offers a 2.63% dividend yield with a 50% payout ratio and 5.4% 3-year growth. Its GF Value suggests a 9.4% undervaluation. LMT has a GF Score of 89/100, with strong profitability and valuation metrics. Institutional guru ownership is robust, but insider activity shows net selling.

gurufocus.com2 min
SEP 29
$LMTMedAI 9/10

Lockheed Martin (LMT) Secures $245M Contract Modification to Exp

Lockheed Martin (LMT) received a $245M contract modification to expand production of F/A-18E/F Infrared Search and Track Block II systems for the U.S. Navy and Royal Australian Air Force. The company offers a 2.63% dividend yield, a 50% payout ratio, and a 3-year dividend growth rate of 5.4%. LMT's stock is trading 9.4% below its GF Value™ of $565.64, with a GF Score™ of 89/100. Institutional investors show mixed sentiment, while insiders have sold $4.0M in shares over the past year.

gurufocus.com2 min
SEP 29
$GMEMed

GameStop: Ryan Cohen reports 8.8% ownership stake

Ryan Cohen reported an 8.8% ownership stake in GameStop (GME), totaling 44,683,306 shares. He owns 40,948,522 shares directly, valued at $185,549,462, and 3,734,784 warrants received as a dividend. Cohen has sole voting and dispositive power over these shares, with no transactions since his last filing.

stocktitan.net1 min